GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Dividend History
Investors can expect a dividend payout of $0.43 per share, scheduled to be distributed in 19 days on October 9, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 9, 2025 | $0.43 | 2025-08-15 | 2025-08-15 |
| July 10, 2025 | $0.43 | 2025-05-16 | 2025-05-16 |
| April 10, 2025 | $0.41 | 2025-02-21 | 2025-02-21 |
| January 9, 2025 | $0.38 | 2024-11-15 | 2024-11-15 |
| October 10, 2024 | $0.39 | 2024-08-16 | 2024-08-16 |
Dividends Summary
- GSK plc American Depositary Shares (Each representing two Ordinary Shares) has issued 91 dividend payments over the past 22 years
- The most recent dividend was paid 72 days ago, on July 10, 2025
- The highest dividend payed out to investors during this period was $0.749616 per share
- The average dividend paid during this period was $0.49 per share.
Company News
The global maternal mental health market is projected to grow from $10.32 billion in 2024 to $126.33 billion by 2034, driven by increasing awareness of perinatal mental health issues, technological advancements, and reduced stigma around mental health conditions.
GSK announced a $30 billion investment in US research, development, and manufacturing over five years, including a new $1.2 billion biologics factory in Pennsylvania for respiratory and cancer treatments.
Dynavax Technologies exceeded Q2 2025 analyst expectations with $95.4 million in revenue and $0.14 EPS, driven by record sales of HEPLISAV-B hepatitis B vaccine and strong market share growth.
The article discusses three stocks that could help recession-proof a portfolio: Star Gas Partners (SGU), Merck & Company (MRK), and GSK. These stocks are seen as undervalued and potentially resilient to economic downturns.
Moderna's stock has outperformed the industry, sector, and S&P 500 in 2023, driven by the strong development of its mRNA-based therapeutics. The company plans to launch 15 new products, including an RSV vaccine, over the next five years, reducing its dependence on the COVID-19 vaccine. Moderna's robust pipeline progress and strong cash position make it an attractive investment option.